TMTP1, a novel tumor-homing peptide, specifically targets hematological malignancies and their metastases

Abstract

TMTP1, a 5-amino acid peptide NVVRQ, obtained by using the flagella peptide library screening in our previous studies, can be used for the labeling of malignant in situ and metastatic lesions, and even micro-metastases. In this study, TMTP1 was assessed for its ability to specifically target the malignant hematopoietic cells and metastatic lesions of hematological malignancies. FITC-TMTP1 was chemically synthesized. Immunofluorescence assay and competitive test were carried out to determine the specific binding capacity of TMTPl to hematological malignant cell lines, including HL60, k562, SHI-1, Jurkat, Raji, El–4 and umbilical cord blood mononuclear cells. Mononuclear cells were isolated from the bone marrow of healthy subjects and patients with chronic myeloid leukemia. Then the cells were co-clutured with TMTP1 or scrambled peptides and the binding and affinity of TMTP1 peptide to the primary cells of hematological malignancies were flow cytometrically analyzed. The binding specificity of TMTP1 to target hematological malignancies was measured in vivo by intravenous injection of FITC-conjugated TMTP1 into El-4 lymphoma-bearing mice. The results showed that TMTP1 specifically bound to the cells of a series of hematological malignancies, including HL60, k562, Jurkat, Raji, El–4 and chronic myeloid leukemia primary cells but not to bone marrow mononuclear cells from healthy subjects. By contrast, TMTP1 could bind to the metastatic foci of lymphoma originating from the EL-4 cell line while the scrambled peptide failed to do so. Moreover, the occult metastases could be identified, with high specificity, by detecting FITC-TMTP1. We are led to conclude that TMTP1, as a novel tumor-homing peptide, can serve as a marker for primary malignant and metastatic lesions for the early diagnosis of hematological malignances and a carrier of anticancer drugs for cancer treatment.

Keywords

hematological malignancies / flow cytometry / TMTP1 / homing peptide / tumor metastasis

References

[1] YangW., LuoD., WangS., WangR., et al.. TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin Cancer Res, 2008, 14(17): 5494-5502

[2] McWhirterJ.R., Kretz-RommelA., SavenA., et al.. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immuno modulation. Proc Natl Acad Sci USA, 2006, 103(4): 1041-1046

[3] Ferrieu-WeisbuchC., MichelS., Collomb-ClercE., et al.. Characterization of prostate-specific antigen binding peptides selected by phage display technology. J Mol Recognit, 2006, 19(1): 10-20

[4] BockmannM., HilkenG., SchmidtA., et al.. Novel SRESPHP peptide medites specific binding to primary medullary thyroid carcinoma after systemic injection. Hum Gene Ther, 2005, 16(11): 1267-1275

[5] AskoxylakisV., ZitzmannS., MierW., et al.. Preclinical evaluation of the breast cancer cell-binding peptide, p160. Clin Cancer Res, 2005, 11(18): 6705-6712

[6] SharonJ., LiebmanM.A., WilliamsB.R.. Recombinant polyclonal antibodies for cancer therapy. J Cell Biochem, 2005, 96(2): 305-313

[7] ZitzmannS., KramerS., MierW., et al.. Identification of a new prostate-specific cyclic peptide with the bacterial FliTrx system. J Nucl Med, 2005, 46(5): 782-785

[8] NigelJ.P., Beasley, PrevoR., et al.. Intratumoral lymphangiogenesis and lymphnode metastasis in head and neck cancer. Cancer Res, 2002, 62(5): 1315-1320

[9] SamoylovaT.I., MorrisonN.E., GlobaL.P., et al.. Peptide phage display: opportunities for development of personalized anti-cancer strategies. Anticancer AgentsMed Chem, 2006, 6(1): 9-17

[10] HuS., GuoX., XieH., et al.. Phage display selec tionof peptides that inhibit metastasis ability of gastricc ancer cells with high liver-metastatic potential. Biochem Biophys Res Commun, 2006, 341(4): 964-972

[11] LandonL.A., ZouJ.. Deutscher SL. Is phage display technology on target for developing peptide-based cancer drugs ?. Curr Drug Discov Technol, 2004, 1(2): 113-132

[12] LuZ., MurrayK.S., Van CleaveV., et al.. Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions. Biotechnology NY, 1995, 13(4): 366-372

[13] FeiP., JunyuN., JiangfengY., et al.. Monoclonal antibodies against human tumor metastasis suppressor gene-1 (TMSG-1): preparation, characterization, and application. Hybrid Hybridomics, 2004, 23(5): 318-325